AFT Pharmaceuticals Achieves Record Revenue and Expands Global Reach

AFT Pharmaceuticals Ltd. ( (AU:AFP) ) has issued an announcement.

AFT Pharmaceuticals reported a record revenue of $208 million for the year ending March 2025, marking a 6% increase from the previous year. Despite challenges such as destocking and a doctors’ strike in South Korea, the company achieved strong growth in its core Australasian market and is targeting $300 million in revenue by 2027. The company continues to invest in long-term growth, expanding its R&D pipeline and launching new products in international markets, including the US and China. AFT Pharmaceuticals’ strategic investments and licensing agreements are expected to enhance shareholder value and solidify its position in the global pharmaceutical market.

More about AFT Pharmaceuticals Ltd.

AFT Pharmaceuticals Ltd. is a diversified pharmaceutical company based in New Zealand, focusing on the development and distribution of pharmaceutical products across Australasian, Asian, and international markets. The company is known for its innovative products, including Maxigesic, and has a strong presence in the pharmaceutical industry with a focus on expanding its reach and product offerings.

Average Trading Volume: 2,348

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$255.3M

For detailed information about AFP stock, go to TipRanks’ Stock Analysis page.